Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 632.51 Billion KRW | 9.46% |
| 2022 | 577.82 Billion KRW | 9.51% |
| 2021 | 527.66 Billion KRW | 26.19% |
| 2020 | 418.15 Billion KRW | 24.94% |
| 2019 | 334.67 Billion KRW | 66.79% |
| 2018 | 200.65 Billion KRW | 12.31% |
| 2017 | 178.66 Billion KRW | 13.34% |
| 2016 | 157.64 Billion KRW | 31.63% |
| 2015 | 119.76 Billion KRW | 4.88% |
| 2014 | 114.19 Billion KRW | 23.82% |
| 2013 | 92.22 Billion KRW | -71.48% |
| 2012 | 323.36 Billion KRW | 2.27% |
| 2011 | 316.2 Billion KRW | 11.83% |
| 2010 | 282.75 Billion KRW | 21.66% |
| 2009 | 232.41 Billion KRW | -6.04% |
| 2008 | 247.35 Billion KRW | 6.88% |
| 2007 | 231.42 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 647.21 Billion KRW | 1.49% |
| 2024 Q1 | 637.73 Billion KRW | 0.82% |
| 2023 FY | 632.51 Billion KRW | 9.46% |
| 2023 Q2 | 611.51 Billion KRW | 2.11% |
| 2023 Q1 | 598.85 Billion KRW | 3.64% |
| 2023 Q4 | 632.51 Billion KRW | -3.4% |
| 2023 Q3 | 654.79 Billion KRW | 7.08% |
| 2022 Q1 | 519.31 Billion KRW | -1.58% |
| 2022 Q2 | 560.92 Billion KRW | 8.01% |
| 2022 Q4 | 577.82 Billion KRW | -0.98% |
| 2022 Q3 | 583.54 Billion KRW | 4.03% |
| 2022 FY | 577.82 Billion KRW | 9.51% |
| 2021 Q4 | 527.66 Billion KRW | 5.06% |
| 2021 Q3 | 502.26 Billion KRW | 15.11% |
| 2021 Q2 | 436.35 Billion KRW | -3.83% |
| 2021 Q1 | 453.73 Billion KRW | 8.51% |
| 2021 FY | 527.66 Billion KRW | 26.19% |
| 2020 Q1 | 374.25 Billion KRW | 11.83% |
| 2020 Q2 | 390.29 Billion KRW | 4.28% |
| 2020 FY | 418.15 Billion KRW | 24.94% |
| 2020 Q3 | 422.23 Billion KRW | 8.18% |
| 2020 Q4 | 418.15 Billion KRW | -0.97% |
| 2019 Q2 | 270.41 Billion KRW | -0.4% |
| 2019 FY | 334.67 Billion KRW | 66.79% |
| 2019 Q4 | 334.67 Billion KRW | 10.37% |
| 2019 Q1 | 271.49 Billion KRW | 35.3% |
| 2019 Q3 | 303.23 Billion KRW | 12.14% |
| 2018 FY | 200.65 Billion KRW | 12.31% |
| 2018 Q1 | 194.95 Billion KRW | 9.12% |
| 2018 Q2 | 191.1 Billion KRW | -1.98% |
| 2018 Q3 | 207.22 Billion KRW | 8.44% |
| 2018 Q4 | 200.65 Billion KRW | -3.17% |
| 2017 FY | 178.66 Billion KRW | 13.34% |
| 2017 Q4 | 178.66 Billion KRW | -2.43% |
| 2017 Q3 | 183.12 Billion KRW | -1.77% |
| 2017 Q2 | 186.41 Billion KRW | -3.15% |
| 2017 Q1 | 192.48 Billion KRW | 22.1% |
| 2016 FY | 157.64 Billion KRW | 31.63% |
| 2016 Q4 | 157.64 Billion KRW | 4.89% |
| 2016 Q2 | 121.17 Billion KRW | -2.57% |
| 2016 Q1 | 124.36 Billion KRW | 3.85% |
| 2016 Q3 | 150.29 Billion KRW | 24.03% |
| 2015 FY | 119.76 Billion KRW | 4.88% |
| 2015 Q4 | 119.76 Billion KRW | -9.28% |
| 2015 Q3 | 132.01 Billion KRW | -18.21% |
| 2015 Q2 | 161.4 Billion KRW | 36.36% |
| 2015 Q1 | 118.36 Billion KRW | 3.66% |
| 2014 Q4 | 114.19 Billion KRW | 17.02% |
| 2014 FY | 114.19 Billion KRW | 23.82% |
| 2014 Q3 | 97.58 Billion KRW | 4.08% |
| 2014 Q2 | 93.76 Billion KRW | -0.45% |
| 2014 Q1 | 94.18 Billion KRW | 2.13% |
| 2013 Q2 | 313.39 Billion KRW | -6.36% |
| 2013 Q3 | 298.38 Billion KRW | -4.79% |
| 2013 Q4 | 92.22 Billion KRW | -69.09% |
| 2013 FY | 92.22 Billion KRW | -71.48% |
| 2013 Q1 | 334.67 Billion KRW | 3.5% |
| 2012 FY | 323.36 Billion KRW | 2.27% |
| 2012 Q4 | 323.36 Billion KRW | 0.0% |
| 2012 Q1 | 243.57 Billion KRW | 0.0% |
| 2011 Q1 | 238.48 Billion KRW | 0.0% |
| 2011 Q3 | 220.3 Billion KRW | -1.15% |
| 2011 FY | 316.2 Billion KRW | 11.83% |
| 2011 Q2 | 222.86 Billion KRW | -6.55% |
| 2010 Q2 | 208.16 Billion KRW | 0.25% |
| 2010 Q1 | 207.63 Billion KRW | 0.0% |
| 2010 FY | 282.75 Billion KRW | 21.66% |
| 2010 Q3 | 208.15 Billion KRW | -0.0% |
| 2009 Q1 | 168.92 Billion KRW | 0.0% |
| 2009 FY | 232.41 Billion KRW | -6.04% |
| 2009 Q3 | 161.92 Billion KRW | -2.33% |
| 2009 Q2 | 165.77 Billion KRW | -1.86% |
| 2008 Q1 | 158.84 Billion KRW | 0.0% |
| 2008 Q2 | 157.13 Billion KRW | -1.08% |
| 2008 Q3 | 160.59 Billion KRW | 2.2% |
| 2008 FY | 247.35 Billion KRW | 6.88% |
| 2007 Q3 | 162.5 Billion KRW | -1.18% |
| 2007 FY | 231.42 Billion KRW | 0.0% |
| 2007 Q1 | 170.8 Billion KRW | 0.0% |
| 2007 Q2 | 164.45 Billion KRW | -3.72% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -712.402% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 31.972% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 10.547% |
| HANDOK Inc. | 449.7 Billion KRW | -40.651% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -638.317% |
| Yuhan Corporation | 712.33 Billion KRW | 11.205% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | -0.096% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -3879.487% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 25.745% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1081.646% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -207.234% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -741.44% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -327.973% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -798.448% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -712.402% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1635.961% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -151.848% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -186.59% |
| JW Holdings Corporation | 827.51 Billion KRW | 23.564% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -44.743% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -7.792% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -66.628% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -697.613% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -804.016% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -160.454% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -91.502% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -712.402% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -29.081% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 26.282% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -66.628% |
| Yuhan Corporation | 712.33 Billion KRW | 11.205% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -32.379% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -361.799% |
| Suheung Co., Ltd. | 516.66 Billion KRW | -22.423% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -66.628% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -309.301% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -603.07% |
| CKD Bio Corp. | 170.76 Billion KRW | -270.413% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -159.512% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -301.2% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1370.319% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -697.613% |
| Boryung Corporation | 373.1 Billion KRW | -69.527% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -203.807% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -207.234% |
| JW Lifescience Corporation | 96.44 Billion KRW | -555.846% |